Ibandronate A bisphosphonate licensed for the treatment of postmenopausal osteoporosis. The drug can be administered orally or by slow intravenous injection. Orally, it is given before meals and washed down with a cup of water; afterwards, the patient must sit and not lie down for 30 min. The oral dose of 150 mg is given once a month, a regimen thought to improve compliance. It can also be administered by slow intravenous injection at a dose of 3 mg in 3ml every 3 months. This is particularly useful in patients with gastrointestinal intolerance of bisphosphonates.
Currently, no topics are attached.
Currently, no resources are attached.
Edit resource New resource